TrialLeukemia & lymphoma2009

A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia.

Thomas S Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.